Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR | P30968 | 7/20 | 0.74 |
| ▸ | DRD1 | P21728 | 1/20 | 0.67 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.67 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.67 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.66 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.56 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.54 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.54 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.54 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Detirelix Acetate SCHEMBL722712 | 1.00 | GNRHR (0.74) | GNRHRDRD1OPRM1MRGPRX2ABCB11 | |
| Detirelix Acetate SCHEMBL29406059 | 0.96 | GNRHR (0.68) | GNRHRDRD1OPRM1MRGPRX2ABCB11 | |
| Detirelix Acetate SCHEMBL422026 | 0.96 | GNRHR (0.68) | GNRHRDRD1OPRM1MRGPRX2ABCB11 | |
| Detirelix Acetate SCHEMBL29893517 | 0.96 | GNRHR (0.68) | GNRHRDRD1OPRM1MRGPRX2ABCB11 | |
| Detirelix Acetate SCHEMBL635713 | 0.95 | GNRHR (0.70) | GNRHRDRD1OPRM1MRGPRX2ABCB11 | |
| Acetic Acid SCHEMBL719624 | 0.92 | GNRHR (0.64) | GNRHRDRD1OPRM1MRGPRX2ABCB11 | |
| Cetrorelix SCHEMBL21174252 | 0.89 | GNRHR (0.84) | GNRHRDRD1OPRM1MRGPRX2ABCB11 | |
| SCHEMBL11099432 | 0.89 | KISS1R (0.63) | GNRHRDRD1OPRM1MRGPRX2ABCB11 | |
| SCHEMBL11207519 | 0.88 | GNRHR (0.61) | GNRHRDRD1OPRM1MRGPRX2ABCB11 | |
| SCHEMBL11200262 | 0.87 | GNRHR (0.59) | GNRHRDRD1OPRM1MRGPRX2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034192-A1 | USE OF GNRH ANTAGONISTS IN MAMMALS TO SYNCHRONIZE FOLLICULAR WAVE EMERGENCE | UNIV SASKATCHEWAN (CA) | 2026-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034192-A1 | USE OF GNRH ANTAGONISTS IN MAMMALS TO SYNCHRONIZE FOLLICULAR WAVE EMERGENCE | GNRHR, FSHR, PGF | GNRHR 1/4885DRD1 1711/4885OPRM1 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.